Table 3.
Toxicity profiles of compound heterozygous DPYD variant allele carriers. Shown per patient are DPYD variants, fluoropyrimidine dose as a percentage of the regular dose, and experienced toxicity with this dose. All patients retrospectively identified as DPYD variants carrier received full doses and experienced severe (CTC-AE ≥ 3) toxicity. All patients prospectively identified as DPYD variant(s) carrier received dose reductions and experienced a maximum of CTC-AE grade 2 toxicity with the initial dose. Abbreviations: CTC-AE: Common Terminology Criteria for Adverse Events v4.03.
| Patient # | DPYD variants | Dose (% of Regular Dose) | Toxicity (Maximal CTC Grade) |
|---|---|---|---|
| 1 | DPYD*2A + c.1236G>A | 100% | 4 |
| 2 | DPYD*2A + c.2846A>T | 50% | 1–2 |
| 3 | c.1236G>A + c.2846A>T | 50% → 70% | 0 (on 50% dose) → 3 (on 70% dose) |
| 4 | DPYD*2A + c.2846A>T | 100% | 5 |
| 5 | DPYD*2A + c.2846A>T | 50% | 0 |
| 6 | DPYD*2A + c.1236G>A | 100% | 4 |
| 7 | DPYD*2A + c.1236G>A | 100% | 3 |